Keyphrases
Liraglutide
100%
Acute Myocardial Infarction
100%
Prolonged Treatment
100%
Cardiac Remodeling
100%
Glucagon-like
40%
Reperfused Myocardial Infarction
40%
Mitochondrial Respiration
40%
Non-compact Myocardium
40%
Cardiac Magnetic Resonance Imaging (cMRI)
40%
Interstitial Fibrosis
40%
Myocardial Infarction
40%
Magnetic Resonance Imaging Analysis
20%
Structural Change
20%
Myocardium
20%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
20%
Infarct
20%
Ligation
20%
Infarcted
20%
Complex Set
20%
Acute Phase
20%
Cardiac Hypertrophy
20%
Rat Model
20%
Phosphorylation
20%
Once-daily
20%
Cardioprotective Agents
20%
Heart Ventricles
20%
Molecular Analysis
20%
Histological Analysis
20%
Placebo
20%
Left Anterior Descending Coronary Artery
20%
Subcutaneous Injection
20%
Left Ventricular End-diastolic Volume (LVEDV)
20%
Heart Failure
20%
Left Ventricular Ejection Fraction
20%
Myocyte Apoptosis
20%
Mitochondrial Fatty Acid Oxidation
20%
Histology
20%
Incretin Hormones
20%
Functional Change
20%
Sham
20%
Sprague-Dawley Rats
20%
Inflammation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Acute Heart Infarction
100%
Heart Ventricle Remodeling
100%
Heart Infarction
80%
Fibrosing Alveolitis
40%
Glucagon-Like Peptide-1
40%
Subcutaneous Injection
20%
Sprague Dawley Rat
20%
Placebo
20%
Rat Model
20%
Inflammation
20%
Mitogen Activated Protein Kinase P38
20%
Fatty Acid
20%
Infarction
20%
Incretin
20%
Congestive Heart Failure
20%